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httpPostexercise phosphocreatine recovery, an index
of mitochondrial oxidative phosphorylation,
is reduced in diabetic patients with lower extremity
complications
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Rosemond A. Villafuerte, BS,b Christos Sampanis, MD,a Charalambos Gnardellis, PhD,c
Chun S. Zuo, PhD,b and Aristidis Veves, MD,a Boston and Belmont, Mass; and Messolonghi, Greece
Objective: To identify differences in postexercise phosphocreatine (PCr) recovery, an index of mitochondrial function, in
diabetic patients with and without lower extremity complications.
Methods: We enrolled healthy control subjects and three groups of patients with type 2 diabetes mellitus: without
complications, with peripheral neuropathy, and with both peripheral neuropathy and peripheral arterial disease. We used
magnetic resonance spectroscopic measurements to perform continuous measurements of phosphorous metabolites
(PCr and inorganic phosphate [Pi]) during a 3-minute graded exercise at the level of the posterior calf muscles
(gastrocnemius and soleus muscles). Micro- and macrovascular reactivity measurements also were performed.
Results: The resting Pi/PCr ratio and PCr at baseline and the maximum reached during exercise were similar in all groups.
The postexercise time required for recovery of Pi/PCr ratio and PCr levels to resting levels, an assessment of mito-
chondrial oxidative phosphorylation, was signiﬁcantly higher in diabetic patients with neuropathy and those with both
neuropathy and peripheral arterial disease (P < .01 for both measurements). These two groups also had higher levels of
tumor necrosis factor-a (P < .01) and granulocyte colony-stimulating factor (P < .05). Multiple regression analysis
showed that only granulocyte colony-stimulating factor, osteoprotegerin, and tumor necrosis factor-a were signiﬁcant
contributing factors in the variation of the Pi/PCr ratio recovery time. No associations were observed between micro- and
macrovascular reactivity measurements and Pi/PCr ratio or PCr recovery time.
Conclusions: Mitochondrial oxidative phosphorylation is impaired only in type 2 diabetes mellitus patients with
neuropathy whether or not peripheral arterial disease is present and is associated with the increased proinﬂammatory state
observed in these groups. (J Vasc Surg 2013;57:997-1005.)Mitochondria are the site of oxidative substrate utiliza-
tion that results in production of adenosine triphosphate. In
the majority of cells of the human body, mitochondria
represent the energy-generating organelle. Mitochondrial
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://dx.doi.org/10.1016/j.jvs.2012.10.011cause either acute or chronic tissue hypoxia, such as periph-
eral arterial disease (PAD), also lead to impaired mitochon-
drial function.1-3 However, accumulating evidence suggests
that the impaired mitochondrial function present in PAD
is not exclusively related to oxygen supply but is also
caused by intrinsic mitochondrial defects in the claudicating
muscle that are similar to those seen in mitochondrial
myopathies.4-6 In addition, mitochondrial dysfunction has
been associated with the presence of diabetes, although
causality is not clear.7-10 Finally, animal studies have sug-
gested that mitochondrial dysfunction contributed to the
development of diabetic neuropathy.11-13
Phosphorus-31 magnetic resonance spectroscopy (31P
MRS) has been used for more than 3 decades to document
muscle energy reserves, metabolism, and function. This
technique is unique in its ability to study continuously
and noninvasively the biochemical pathways for the supply
and utilization of energy.14 Moreover, by measuring the
postexercise rate of phosphocreatine (PCr) resynthesis, an
almost pure oxidative process, 31P MRS is capable of
detecting defects in mitochondrial oxidative phosphoryla-
tion, one of the most important functions of the
mitochondria.15
Currently little information is available regarding
changes in themuscle energy reserves and themitochondrial997
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without lower extremity complications. The main aim of
this study was to identify the contribution of diabetic periph-
eral neuropathy (DPN), mild PAD, and inﬂammation to
these parameters. Our primary hypothesis was that periph-
eral neuropathy would affect mitochondrial oxidative phos-
phorylation and the combination of both DPN and PAD
would result in further compromise.
METHODS
Subjects. All research subjects were recruited from
ambulatory patients who attended the Joslin-Beth Israel
Deaconess Foot Center, located at the Beth Israel
Deaconess Medical Center. We studied ﬁve groups of
subjects age 40-80 years: the ﬁrst group included healthy
control subjects (C), the second type 2 diabetic (T2DM)
patients without PAD or DPN (DM), the third T2DM
patients with DPN but no PAD (DM-DPN), the fourth
T2DM patients with both DPN and PAD (DM-DPN-
PAD), and the ﬁfth type 1 diabetic patients (T1DM) with
lower extremity complications (DPN with or without
PAD). Peripheral arterial disease was diagnosed as ankle-
brachial index (ABI) 0.9-0.41 and, in case of noncom-
pressible vessels, Rutherford 0 and 1 PAD based on toe
pressures and pulse volume recordings and/or Doppler
measurements performed at the vascular laboratory.
Exclusion criteria were (1) presence of a foot ulcer; (2)
cardiovascular disease as demonstrated in only the
following instances: (a) congestive heart failure with severe
peripheral edema, (b) transient ischemic attack within the
past 6 months, or (c) stroke with residual neurologic
damage; (3) uncontrolled hypertension: systolic blood
pressure >180 mm Hg or diastolic blood pressure >105
mm Hg; (4) presence of any serious disease including end-
stage renal failure requiring dialysis or renal transplantation,
active malignant disease requiring treatment, or hepatic,
hematologic, neurologic, or immune disease; (5) subject
with known alcohol or drug abuse problems; (6) treatment
with oral or parenteral corticosteroids or immunosuppres-
sive or cytotoxic agents; (7) presence of known infectious
disease (including human immunodeﬁciency virus, hepa-
titis B and C); (8) subject has any condition(s) that seri-
ously compromises the patient’s ability to complete this
study, including frailty; (9) known history of myopathy
and/or a creatine kinase level during the screening visit
three times higher than the upper normal limit; and (10)
smoking/tobacco use. The institutional review board of
the Beth Israel Deaconess Medical Center and the McLean
Hospital approved this study.
Study methods. All participants were recruited in
consecutive order at the Joslin-Beth Israel Deaconess
Foot Center over a period of 12 months. All participants
ﬁrst attended the Joslin-Beth Israel Deaconess Foot Center
and underwent the same set of tests, which included a full
medical history, complete physical examination, charac-
terization of neuropathy, ABI, vascular reactivity, and
blood drawing for evaluation of cytokines and insulin
resistance measurement. They subsequently attended theradiology department of the McLean Hospital where
muscle energy reserve measurements were performed.
Characterization of the neuropathy. The symptoms
of DPN were evaluated by using a neuropathy symptom
score and the clinical signs by using a neuropathy disability
score (NDS). Quantitative sensory testing included assess-
ment of the vibration perception threshold using a bio-
thesiometer and cutaneous perception threshold using
Semmes-Weinstein monoﬁlaments. Details about these
tests have been described elsewhere.16 Diabetic neuro-
pathic patients were required to have severe neuropathy
(NDS >5) and to have clinical neuropathy up to the
midcalf level. This ensured that peripheral neuropathy was
present at the level of muscle measurements.
Evaluation of PAD. Peripheral arterial disease was
diagnosed according to the American College of Cardi-
ology/American Heart Association guidelines.17 Diabetic
patients with mild peripheral vascular disease based on ABI
and/or clinical features were recruited.
Assessment of vascular reactivity. Vascular reactivity
at the microcirculation of the dorsum of the foot using
iontophoresis of acetylcholine and sodium nitroprusside
was evaluated using laser Doppler iontophoresis (MIC1
iontophoresis system; Monitor Moor Instruments Ltd,
Millwey, Devon, England) and a laser Doppler perfusion
imager (Lisca PIM 2.0; Lisca Development AB, Linkoping,
Sweden) as previously described.18 Skin oxygenation was
measured using the medical hyperspectral imaging tech-
nique (HyperMed OxyView MHSI System; HyperMed,
Inc, Watertown, Mass). The medical hyperspectral images
were obtained from the same site where vascular reactivity
was measured. Data were analyzed ofﬂine using decom-
position, image processing, and image registration tech-
niques as previously described.18 Endothelium dependent
(ﬂow-mediated dilation) and independent (nitroglycerin-
induced dilation) vasodilation of the macrocirculation were
assessed at the brachial artery with a 10.0-MHz linear array
transducer (Aloka Prosound a7; Hitachi Aloka Medical
Ltd, Tokyo, Japan) according to established guidelines.19
The MRS measurements of muscle energy reserves
(31P metabolites). Participants attended the Magnetic
Resonance Imaging Center of the McLean Hospital for
31P spectroscopic measurements. All subjects were asked
to be in the fasting state and were advised to avoid stren-
uous exercise for 24 hours before testing. The subjects res-
ted in a warm room for 30 minutes before testing. The 31P
MRS data were acquired on a Siemens 3T whole body
magnetic resonance scanner (TIMTrio; Siemens AG, Erlan-
gen, Germany). Subjects were placed supine on a magnetic
resonance-compatible exercise bed. The leg identiﬁed to
have PAD according to the inclusion criteria was restrained
at the ankle and placed on a foot pedal mounted to an
isotonic ergometer.1 An 1H/31P double-tuned surface
radiofrequency coil designed for this study was fastened to
the underbelly of the calf muscle. Prior to 31P data acquisi-
tion, shimming was performed with proton signal to achieve
better homogeneity of the static ﬁeld, and proton (1H) spin-
echo images were acquired for detailed images of the
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ergometer placed in the MRI scanner, as previously
described.1 The 31P metabolite spectra were acquired
kinetically with four signal averages per spectrum within 6
seconds. Initially, 20 baseline spectra were collectedwith the
subject resting. The subject then was asked to push against
the pedal to isometrically exercise the posterior compart-
ment muscles for 3 minutes and then relaxed for approxi-
mately 15 minutes. The amount of force applied on the
pedal was recorded and averaged over the 3-minute exercise
period and was used to evaluate the working capacity of the
calf muscles. The 31PMRS data were acquired at a temporal
resolution of six sections during resting and exercise. The
inorganic phosphate (Pi) and PCr information was extracted
from the data as previously reported by our unit.18,20
Cytokine measurements. Cytokines and growth
factors were measured using a Luminex 200 apparatus
(Luminex, Austin, Tex) and Millipore multiplex immuno-
assay panels (Millipore, Chicago, Ill). Serum specimens
were obtained during resting and stored at 80C until
they were analyzed together during the ﬁrst thaw at the
end of the study. In order to test the reliability of the multi-
plex assay measurements, insulin levels were measured
using our standard hospital laboratory and the multiplex
assay. We found a very satisfactory correlation (r ¼ 0.9).
Using a 39-plex platform, we performed two repeated
measurements on the same samples and noted very satisfac-
tory correlations. The intra- and interassay coefﬁcient vari-
ations of the performed cytokine measurements, as
provided by the manufacturer (Millipore), were similar to
measurements performed using standard enzyme-linked
immunosorbent assay techniques in our unit.21
Insulin resistance measurements. Insulin resistance
was assessed using the homeostasis model assessment
(HOMA), which is based on a mathematical correlation
of fasting plasma glucose and insulin levels.22 Patients
who were treated with insulin were excluded. As a result,
measurements were available in the healthy control sub-
jects, the diabetic group with no complications, and the
diabetic group with neuropathy.
Data analysis. Analysis was undertaken by univariate
techniques and by modeling the data through multiple
linear regression using the Minitab (State College, Pa)
statistical package. For normally distributed data, the anal-
ysis of variance procedure was used, followed by Fisher post
hoc multiple comparison tests to identify differences
among the various groups. For nonparametrically distrib-
uted data, the Kruskal-Wallis test was used. Multiple
regression analysis was used to assess signiﬁcant contrib-
uting factors in the variation of the Pi/PCr ratio and PCr
recovery time between the four study groups. The Pearson
correlation coefﬁcient r was used for correlation of different
parameters in the same group.
RESULTS
Comparisons of the demographics and of the vascular
reactivity results are summarized in Table I. The ﬂow-
mediated dilation was lower in all three diabetic groupscompared with healthy controls and further reduced in
the groups with neuropathy and PAD compared with the
diabetic group without complications (P < .05). As
expected, a higher number of diabetic patients were treated
with medications that can affect endothelial function such
as antihypertensives (angiotensin-converting enzyme inhib-
itors and angiotensin receptor blockers) and statins
compared with healthy controls. The ABI was measurable
in six patients with peripheral neuropathy and PAD
(mean [standard deviation] 0.86 [0.1]). The remaining
four subjects had already been diagnosed at the vascular
laboratory before their recruitment in the study. All of
them had tibial occlusive disease, and one subject also
had subcritical iliac stenosis. Eight subjects had Rutherford
0 and two Rutherford 1 PAD.
The results from measurements of the various growth
factors, cytokines, and cellular adhesion molecules are
given in Table I. Tumor necrosis factor-a (TNF-a) was
higher in both diabetic groups with complications
compared with healthy controls and with the diabetic
group without complications (P < .01). The granulocyte-
colony stimulating factor (G-CSF) level was higher in the
two diabetic groups with complications compared with
healthy controls, whereas the diabetic group with neurop-
athy and PAD had higher levels compared with the other
two diabetic groups (P < .05). Osteoprotegerin (OPG)
was higher in the diabetic group with neuropathy and
PAD compared with healthy controls and with the diabetic
group without complications (P < .01). Monocyte chemo-
attractant protein-1 was higher in the diabetic patients
without complications and the group with neuropathy
and PAD compared with healthy controls and in the dia-
betic group without complications compared with the dia-
betic group with neuropathy (P < .01). C-reactive protein
(CRP) also was higher in the two groups with complica-
tions compared with the diabetic group without complica-
tion (P < .05). Insulin resistance, assessed by the HOMA
model, was higher in the group with neuropathy (6.68
[1.90-14.72]); ﬁrst, third quartiles; six patients] compared
with healthy controls (1.28 [0.52-3.61]); P < .05).
However, no differences existed between the diabetic
group without complications (4.21 [1.67-6.43]; nine
patients) and the control subjects or the diabetic patients
with neuropathy.
Muscle metabolism measurements, Pi/PCr ratio, and
PCr are summarized in Table II. There was no difference
within groups for Pi/PCr levels at baseline, maximum level
reached during exercise, and postexercise levels. The time
to Pi/PCr postexercise recovery was higher in the two dia-
betic groups with complications compared with both
healthy controls and the diabetic group without complica-
tions (P < .01; Fig). Similar results were also observed
when PCr levels were evaluated. Thus, no differences
existed among all four groups at the PCr levels at baseline,
minimum reached level during exercise, and postexercise
levels. However, the time to PCr postexercise recovery
was higher in the diabetic groups with complications
compared with the other two groups (P < .01).
Table I. Clinical characteristics and cytokines resultsa
Controls (C)
T2DM patients with
no complications
(DM)
T2DM patients with
neuropathy
(DM-DPN)
T2DM patients with
neuropathy and PAD
(DM-DPN-PAD)
No. 14 11 10 7
Age, years 55 (11) 63 (9) 63 (10) 66 (7)
Males 8 (57%) 6 (55%) 4 (40%) 5 (71%)
T2DM — 11 (100%) 10 (100%) 7 (100%)
DM duration, years — 12 (8) 20 (14) 23 (10)
Body mass index, kg/m2 26.9 (6.4) 30.7 (4.5) 32.7 (8.7) 32.2 (4.6)
Glucoseb 89 (12) 119 (23) 118 (48) 158 (61)
Hemoglobin A1c
c 5.8 (0.5) 7.1 (0.7) 6.7 (0.9) 8.2 (1.2)
Creatinine,d mg/dL 1.0 (0.2) 1.0 (0.2) 1.2 (0.5) 1.3 (0.4)
Neuropathy symptom scoree 0 (0) 3 (3) 5 (5) 5 (5)
NDSf 0 (0) 1 (1) 11 (5) 16 (5)
Vibration perception threshold,g
volts
8 (4) 19 (9) 39 (15) 39 (16)
Semmes-Weinstein monoﬁlamentsh 3.88 (0.14) 4.29 (0.52) 6.11 (1.45) 6.47 (0.80)
Flow-mediated dilation,i % 6.9 (1.3) 5.1 (1.4) 4.6 (2.1) 3.2 (1.3)
Nitroglycerin-induced dilation, % 13.1 (5.2) 11.5 (3.7) 11.4 (1.7) 9.3 (6.7)
Resting foot skin blood ﬂow,
arbitrary units
0.87 (0.15) 0.88 (0.21) 0.83 (0.17) 0.75 (0.16)
Foot oxyhemoglobin,
arbitrary units
37 (15) 38 (21) 39 (21) 30 (17)
Foot deoxyhemoglobin,
arbitrary units
45 (13) 54 (12) 50 (16) 47 (10)
Statin treatment 2 (14%) 9 (82%) 7 (70%) 6 (86%)
Antihypertensives
(angiotensin-converting enzyme
inhibitors, angiotensin
receptor blockers)
1 (7%) 6 (55%) 7 (70%) 2 (29%)
Oral hypoglycemic agent treatment 0 (0%) 7 (64%) 6 (60%) 2 (29%)
Insulin treatment 0 (0%) 2 (18%) 4 (40%) 6 (86%)
TGFa, pg/mL 6.62 (2.77:9.47) 6.24 (4.06:8.34) 4.69 (2.37:10.79) 11.0 (5.06:13.50)
VEGF, pg/mL 157 (64:268) 136 (75:209) 136 (33:262) 232 (174:267)
Insulin,j pg/mL 255 (112:622) 343 (216:737) 970 (255:1521) 2358 (710:6006)
OPG,k pg/mL 617 (390:1442) 573 (440:713) 726 (494:2550) 1820 (800:3334)
OPN, ng/mL 26.1 (18.4:39.3) 19.3 (11.2:23.2) 31.2 (13.6:68.2) 38.2 (20.6:70.3)
G-CSF,l pg/mL 18.9 (13.2:31.5) 23.1 (17.4:32.0) 35.8 (25.5:40.4) 58.4 (40.8:119.0)
Monocyte chemoattractant
protein-1,m pg/mL
343 (208:437) 575 (450:706) 414 (284:558) 516 (298:760)
TNF-a,n pg/mL 4.41 (3.69:8.10) 6.02 (4.97:7.79) 9.11 (7.05:13.68) 9.95 (8.99:28.10)
CRP,o mg/mL 5.53 (1.35:11.97) 2.13 (1.08:4.04) 14.30 (3.59:40.10) 10.91 (6.29:24.94)
CRP, C-reactive protein; DM, diabetes mellitus; DPN, diabetic peripheral neuropathy; G-CSF, granulocyte colony-stimulating factor; NDS, neuropathy
disability score; OPG, osteoprotegerin; OPN, osteopontin; PAD, peripheral arterial disease; SD, standard deviation; T2DM, type 2 diabetes mellitus; TGFa,
tumor growth factor alpha; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
aData is given as no. (%), mean (SD), or median (ﬁrst:third quartile).
bC vs DM-DPN-PAD: P < .05.
cC vs DM, DM-DPN, DM-DPN-PAD; DM, DM-DPN vs DM-DPN-PAD: P < .0001.
dC, DM vs DM-DPN-PAD: P < .05.
eC vs DM-DPN, DM-DPN-PAD: P < .05.
fC, DM vs DM-DPN, DM-DPN-PAD; DM-DPN vs DM-DPN-PAD: P < .0001.
gC vs DM, DM-DPN, DM-DPN-PAD; DM vs DM-DPN, DM-DPN-PAD: P < .0001.
hC, DM vs DM, DM-DPN, DM-DPN-PAD: P < .0001.
iC vs DM, DM-DPN, DM-DPN-PAD; DM vs DM-DPN-PAD: P < .0001.
jC, DM vs DM-DPN-PAD: P < .005.
kC, DM vs DM-DPN-PAD: P < .05.
lC vs DM-DPN, DM-DPN-PAD; DM, DM-DPN vs DM-DPN-PAD: P < .01.
mC vs DM, DM-DPN-PAD; DM vs DM-DPN: P < .01.
nC, DM vs DM-DPN, DM-DPN-PAD: P < .01.
oDM vs DM-DPN, DM-DPN-PAD: P < .05.
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cant correlations were observed between Pi/PCr ratio
recovery time and age (r ¼ 0.33; P < .05), NDS
(r ¼ 0.51; P < .001), OPG (r ¼ 0.59; P < .0001), andmarginally with TNF-a (r ¼ 0.30; P ¼ .059). Multiple
regression analysis showed that, after adjusting for age,
body mass index, gender, and group participation of study
subjects, only G-CSF, OPG, and TNF-a were signiﬁcant
Fig. Time to phosphocreatine (PCr) postexercise recovery was
increased in type 2 diabetes mellitus (T2DM) patients with
peripheral neuropathy (DM-DPN) and T2DM patients with
peripheral neuropathy and peripheral arterial disease (DM-DPN-
PAD) compared with healthy subjects (C) and T2DM patients
without complications (DM). * vs {: P < .01.
Table II. Pi/PCr ratio and PCr MRS measurementsa
Controls (C)
T2DM patients with
no complications
(DM)
T2DM patients
with neuropathy
(DM-DPN)
T2DM patients with
neuropathy and PAD
(DM-DPN-PAD)
Average applied force during exercise 15.8 (4.4) 14.4 (5.9) 13.4 (4.6) 12.7 (4.0)
Resting Pi/PCr ratio before exercise 0.14 (0.04) 0.14 (0.03) 0.13 (0.04) 0.12 (0.05)
Maximal Pi/PCr ratio during exercise 0.50 (0.27) 0.49 (0.25) 0.57 (0.27) 0.55 (0.24)
Resting postexercise Pi/PCr ratio 0.13 (0.05) 0.13 (0.03) 0.12 (0.03) 0.11 (0.06)
Pi/PCr ratio area under the curve 7.18 (6.30) 7.19 (5.8) 9.4 (5.6) 9.4 (5.1)
Postexercise recovery time for Pi/PCr
ratio,b seconds
58 (25) 61 (15) 85 (27) 90 (24)
Resting PCr level before exercise 41,488 (14,907) 48,863 (25,069) 44,214 (16,518) 50,608 (25,193)
Minimal PCr level during exercise 22,313 (7687) 30,473 (17,707) 28,211 (13,940) 27,268 (18,091)
Resting postexercise PCr level 41,704 (14,895) 48,508 (24,591) 46,218 (17,520) 50,632 (25,646)
PCr area under the curve 531 (378) 511 (547) 501 (312) 723 (355)
Postexercise recovery time for PCr
level,c seconds
87 (42) 76 (32) 121 (33) 121 (15)
DM, Diabetes mellitus; DPN, diabetic peripheral neuropathy;MRS, magnetic resonance spectroscopy; PAD, peripheral arterial disease; PCr, phosphocreatine;
Pi, inorganic phosphate; T2DM, type 2 diabetes mellitus.
aData is given as mean (standard deviation).
b,cC, DM vs DM-DPN, DM-DPN-PAD: P < .01.
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recovery time. The PCr recovery time correlated with age
(r ¼ 0.35; P < .05), NDS (r ¼ 0.50; P < .001), OPG
(r ¼ 0.41; P < .01) and osteopontin (OPN; r ¼ 0.41;
P < .01). A second multiple regression model showed
that, after adjusting for age, body mass index, gender,
and group participation, there was no signiﬁcant contrib-
uting factor in the variation of Pi/PCR ratio or PCr ratio
recovery times. Finally, no correlations were observed
between insulin resistance, assessed by the HOMA model,
and the Pi/PCR ratio or PCr recovery times.
We also studied seven T1DM patients with lower
extremity complications, four with neuropathy alone and
three with both neuropathy and PAD. As in the case of
T2DM patients, there was no difference between patients
with neuropathy alone and patients with both neuropathy
and PAD (data not shown), and they all were considered
as one group. Comparisons with the control group andthe T2DM patients with lower extremity complications
are shown in Table III.
DISCUSSION
The main ﬁndings of the present study are that the
postexercise time of recovery of the Pi/PCr ratio and
PCr levels, a measurement of mitochondrial oxidative
phosphorylation, was equally present in T2DM patients
with peripheral neuropathy and patients with both periph-
eral neuropathy and mild PAD. In contrast, no differences
were observed between healthy controls and type 2 dia-
betic subjects without long-term complications. In addi-
tion, the two diabetic groups with complications had
increased inﬂammatory cytokines, and the observed
increases were strongly associated with the observed mito-
chondrial dysfunction.
Peripheral arterial disease has been shown to affect
mitochondrial oxidative phosphorylation assessed by
MRS, but these abnormalities are uncoupled from tissue
perfusion, suggesting an intrinsic mitochondrial problem.1,6
In the present study, we ﬁrst reported that T2DM patients
with peripheral neuropathy in the absence of PAD had
similar impairment as those with both peripheral neurop-
athy and mild PAD. In addition, no associations were
observed between mitochondrial oxidative phosphorylation
and skin blood ﬂow and oxygenation. No associations
existed with endothelium-dependent vasodilation in the
macrocirculation as assessed by ﬂow-mediated dilation,
which, as would be expected from previous studies, was
impaired in all three diabetic groups.23 These data are in
agreement with the previously observed uncoupling
between tissue perfusion and mitochondrial oxidative phos-
phorylation and indicate that impaired mitochondrial oxida-
tive phosphorylation is not associated with changes in
vascular reactivity.6
The causality in the observed association between mito-
chondrial oxidative phosphorylation and peripheral
Table III. Comparison between T1DM and T2DM patientsa
Controls (C)
T2DM patients with
no complications
(T2DM)
T2DM patients with
complications
(T2DM-Compl)
T1DM patients with
complications
(T1DM-Compl)
No. 14 11 17 7
Age, years 55 (11) 63 (9) 64 (9) 57 (9)
Males 8 (57%) 6 (55%) 9 (53%) 6 (86%)
DM duration,b years — 12 (8) 21 (13) 39 (17)
Body mass index, kg/m2 26.9 (6.4) 30.7 (4.5) 32.5 (7.1) 28.4 (6.0)
Hemoglobin A1c
c 5.8 (0.5) 7.1 (0.7) 7.3 (1.2) 8.0 (0.8)
OPG,d pg/mL 617 (390:1442) 573 (440:713) 887 (686:2863) 1435 (870:2388)
OPN,e ng/mL 26.1 (18.4:39.3) 19.3 (11.3:23.2) 33.4 (17.7:67.7) 60.4 (38.3:69.6)
G-CSF,f pg/mL 18.9 (13.2:31.5) 23.1 (17.4:32.0) 38.2 (28.2:54.3) 20.8 (14.5:34.8)
Monocyte chemoattractant
protein-1,g pg/mL
343 (208:437) 575 (450:706) 435 (298:602) 370 (297:409)
TNF-a,h pg/mL 4.41 (3.69:8.10) 6.02 (4.97:7.79) 9.95 (7.78:15.89) 9.92 (5.23:18.7)
C-reactive protein, mg/mL 5.53 (1.35:11.97) 2.13 (1.08:4.04) 10.91 (4.54:33.94) 2.59 (1.59:19.03)
Average applied force 15.8 (4.4) 14.4 (5.9) 13.1 (4.3) 11.9 (3.2)
Pi/PCr ratio resting level 0.14 (0.04) 0.14 (0.03) 0.13 (0.05) 0.12 (0.03)
Pi/PCr ratio exercise maximal level 0.50 (0.27) 0.49 (0.25) 0.56 (0.25) 0.49 (0.25)
Pi/PCr ratio postexercise level 0.13 (0.05) 0.13 (0.03) 0.12 (0.04) 0.11 (0.04)
Pi/PCr ratio postexercise recovery
time,i seconds
58 (25) 61 (15) 87 (25) 86 (13)
PCr resting level 41,488 (14,907) 48,863 (25,069) 46,846 (20,050) 35,570 (19,243)
PCr exercise minimal level 22,313 (7687) 30,473 (17,707) 27,822 (15,240) 24,214 (17,190)
PCr postexercise level 41,704 (14,895) 48,508 (24,591) 48,036 (20,599) 36,484 (19,022)
PCr postexercise recovery
time,j seconds
87 (42) 76 (32) 121 (27) 104 (16)
DM, Diabetes mellitus; G-CSF, granulocyte colony-stimulating factor; OPG, osteoprotegerin; OPN, osteopontin; PCr, phosphocreatine; Pi, inorganic
phosphate; SD, standard deviation; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TNF, tumor necrosis factor.
aData is given as no. (%), mean (SD), or median (ﬁrst:third quartile).
bT1DM-Compl vs T2DM, T2DM-Compl: P < .001.
cC vs T2DM, T2DM-Compl, T1DM-Compl; T2DM vs T1DM-Compl: P < .0001.
dC vs T1DM-Compl; T2DM vs T2DM-Compl, T1DM-Compl: P < .02.
eC vs T1DM-Compl; T2DM vs T2DM-Compl, T1DM-Compl: P < .01.
fC, T2DM, T1DM-Compl vs T2DM-Compl: P < .01.
gC vs T2DM: P < .02.
hC vs T2DM-Compl, T1DM-Compl; T2DM vs T2DM-Compl: P < .01.
iC, T2DM vs T2DM-Compl, T1DM-Compl: P < .001.
jC, T2DM vs T2DM-Compl: P < .01.
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well-known direct effects of neuropathy on muscle function
that lead to muscle atrophy and, therefore, mitochondrial
oxidative phosphorylation. Animal studies have indicated
that dorsal root ganglia neuron mitochondrial dysfunction
and imbalance between mitochondrial biogenesis and
ﬁssion are involved in the development of sensory neurop-
athy.11-13 However, no previous human studies have specif-
ically explored this issue. Human studies have shown that
different mitochondrial haplogroups are signiﬁcantly associ-
ated with an increased risk of speciﬁc diabetes complications
and that the H3 haplogroup is speciﬁcally associated with
the development of neuropathy.24 Therefore, the possibility
that impaired mitochondrial function in various tissues and
cells, such as muscle and neurons, is the primary event that
causes diabetes complications cannot be excluded and
needs further investigation. If this hypothesis proves
correct, it can lead to new therapeutic approaches for the
management of diabetic lower extremity problems.
Previous studies that used this technique have reported
impaired mitochondrial oxidative phosphorylation in thevastus lateralis muscle at the thigh of subjects with extreme
insulin resistance and in type 2 diabetic patients.7-9
However, another study reported no impairment at the
same muscle in patients with short or long duration of
T2DM without any serious diabetic complications and in
subjects with prediabetes.10 In the present study, no differ-
ence was observed between diabetic patients without
complications, all of who had type 2 diabetes of long dura-
tion, and healthy controls. However, although the inﬂam-
matory status of both groups was similar, it was
considerably increased in the two groups with complica-
tions, which also had impaired mitochondrial oxidative
phosphorylation. In addition, TNF-a, G-CSF, and OPG
were the only independent variables associated with the
postexercise time of recovery for the Pi/PCr ratio. These
results indicate that the diabetes complications-related
proinﬂammatory state was the main factor that may have
inﬂuenced mitochondrial oxidative phosphorylation. To
our knowledge, no previous studies have directly examined
the interaction between inﬂammation and mitochondrial
function in the past. However, previous studies have
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by activated macrophages, impairs oxidative phosphoryla-
tion through peroxisome proliferator-activated receptor
(PPAR)-g signaling.25
The ﬁnding of the present study regarding the lack of
proinﬂammatory status in the diabetic patients without
complications even though they all had type 2 diabetes
for an average period of 12 years is intriguing. Similar
results, namely, lack of a proinﬂammatory status in diabetic
patients without complications and long duration of dia-
betes whereas it was present in patients with peripheral
neuropathy, were observed in a previous study in our
unit that used similar techniques and included 212
subjects.26 Elevated serum TNF-a levels were also found
in another study to be associated with decreased renal func-
tion in T1DM patients without proteinuria.27 These ﬁnd-
ings raise the hypothesis that the coexistence of diabetes
and a proinﬂammatory state leads to the development of
mitochondrial oxidative phosphorylation and long-term
complications, whereas in the absence of inﬂammation no
complications develop. The factors that are associated
with the high inﬂammatory status in patients with compli-
cations are not clear and may be related to genetic factors,
diet, lifestyle, or environmental factors. Further studies
exploring this hypothesis are required that can lead to tar-
geting inﬂammation for the management of diabetic
complications.
Osteoprotegerin, a member of the TNF receptor
superfamily 11B, which acts as a decoy receptor activator
of nuclear factor kappaB ligand (RANKL), and OPN
were initially thought to be mainly involved in bone
remodeling. However, recent studies have indicated that
these cytokines are also involved in muscle function.
Thus, OPG has been associated with left ventricular hyper-
trophy and the development of coronary artery
disease.28,29 Osteopontin has been reported to play a role
in the proinﬂammatory state and ﬁbrosis present in dystro-
phic mouse muscle and is increased in muscle biopsies from
subjects with Duchenne muscular dystrophy.30 In addition,
OPN is greatly upregulated in regenerating muscle and
promotes macrophage inﬁltration in necrotic muscle.31
The present study is the ﬁrst to describe an association
between these two cytokines and impaired mitochondrial
oxidative phosphorylation in diabetic patients with neurop-
athy. Further studies are required to establish the mecha-
nisms that are involved and whether manipulation of the
expression of these cytokines can have an effect on muscle
mitochondrial function.
Previous studies in our unit have shown foot muscle
atrophy and reduced PCr levels in diabetic patients with
diabetic neuropathy and increased Pi/PCr ratio at resting
conditions in both nonneuropathic and neuropathic dia-
betic patients.18,20,32 In the present study, no differences
were observed at resting conditions among the four tested
groups, and this ﬁnding is in agreement with previous
studies that included patients with PAD.1,6 The main
reason for this difference between the foot and calf muscles
probably is the fact that neuropathy and severe tissuehypoxia mainly affect the foot muscles, causing consider-
ably more severe muscle atrophy and dysfunction.
However, no studies are available regarding mitochondrial
oxidative phosphorylation of the foot muscles. No differ-
ences in the resting levels of PCr of healthy controls and
patients with type 2 diabetes have been previously re-
ported,8 although a study that included insulin-resistant
offspring of patients with type 2 diabetes reported a 20%
reduction in the Pi/PCr ratio compared with healthy
controls.33 Whether this reduction in the Pi/PCr ratio is
restricted in the prediabetic state and what factors may be
associated with this ﬁnding are unclear.
In the present study, we evaluated both the Pi/PCr
ratio and the PCr level changes during exercise. The
main reason for this focus was that our previous studies
involving foot muscles showed a reduction in resting total
31P concentration, which is mainly comprised of PCr, due
to muscle atrophy.18,20,32 The fact that both Pi/PCr ratio
and PCr measurements showed similar results, especially
regarding changes in postexercise recovery, clearly
strengthens the validity of our results. Of note, the Pi/PCr
ratio postexercise recovery time tended to be shorter than
the PCr postexercise recovery time in all groups. This
ﬁnding is compatible with the ﬁnding of previous studies
that indicated different kinetics between Pi and PCr and
attributed it to a Pi “undershoot” due to its intracellular
redistribution into different compartments.34,35
The HOMA model was used to measure insulin resis-
tance, and, as a result, these measurements were restricted
in patients not treated with insulin. Nonetheless, our
results indicate that there were no differences between dia-
betic patients without complications and those with periph-
eral neuropathy. In addition, no correlations were observed
between insulin resistance and the Pi/PCR ratio and PCr
recovery times. Furthermore, we included a group of
T1DM patients with similar demographics and peripheral
neuropathy with or without PAD and observed no differ-
ences between T1DM and T2DM with regard to mito-
chondrial oxidative phosphorylation. These results
strongly indicate that the type of diabetes, and therefore
the presence and severity of insulin resistance, does not
affect mitochondrial oxidative phosphorylation once lower
extremity complications are present. Our ﬁndings are in
agreement with previous studies that reported impaired
mitochondrial function in T1DM.36 It is of interest that
both T1DM and T2DM patients with lower extremity
complications had similar increases in OPG, OPN, and
TNF-a, another indication of the association of these cyto-
kines with mitochondrial oxidative phosphorylation.
The current study has its limitations. First, although
the groups were matched for age, the control group was
slightly younger. However, it would be expected that this
could have resulted in better mitochondrial oxidative phos-
phorylation compared with DM patients without complica-
tions, and the lack of such a ﬁnding, if anything,
strengthens the conclusion that there are no differences
between these two groups. Furthermore, the most inter-
esting ﬁnding of the present study is the observed
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complications and the two T2DM groups with complica-
tions. The fact that all three groups were matched for all-
important parameters that could affect the results, such as
treatment with statins, antihypertensives, and insulin,
further validates our ﬁndings.
Another limitation is that no patients with diabetes and
PAD but without neuropathy were investigated, mainly
because it is almost impossible to identify such patients
given that neuropathy usually precedes the development
of PAD. However, the fact that patients with neuropathy
alone and those with both neuropathy and PAD had similar
impairment of mitochondrial oxidative phosphorylation
and proinﬂammatory state indicates that the two condi-
tions do not have any additive effects. Furthermore,
previous studies of patients with PAD included both dia-
betic and nondiabetic patients and did not ﬁnd any associ-
ation between diabetes and PCr recovery time.6,37
CONCLUSIONS
Our results indicate that mitochondrial oxidative phos-
phorylation is impaired only in diabetic patients with neurop-
athy with or without PAD and is associated with the
increased proinﬂammatory state observed in these groups.
Further studies are required to examine the role of inﬂamma-
tion in the development of impaired mitochondrial oxidative
phosphorylation and lower extremity complications.
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